This model provides an overview for the management of patients receiving third-line treatment where limited evidence currently exists. Vortioxetine, with its novel mechanism of action, is expected to be a dominant treatment option versus relevant comparators in the UK.
A525(ICERs). Results: Our model has shown that under base case scenario maintenance treatment with buprenorphine/naloxone dominated detoxification with buprenorphine/naloxone by saving 281 TL (cca € 86) and gaining 0.140 QALY per patient over one year. With low dose of treatment (2 mg) the dominance of maintenance treatment over detoxification was retained, while at the high dose, resulting ICER amounted to 5,300 TL/QALY (cca. € 1,615/QALY). Modification of other modeling parameters confirmed our findings. ConClusions: Results of our study suggest that in Turkey maintenance treatment with buprenorphine/naloxone combination is at least costeffective (and may be even cost-saving) versus detoxification with buprenorphine/ naloxone combination. These pharmacoeconomic results are particularly important for those patients who have the need to be less stigmatized when accessing care.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.